Ifp Advisors, Inc Humanigen, Inc Transaction History

Ifp Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$0.09 - $0.2 $63 - $140	-700 Reduced 50.0%	700 $7,000
Q2 2022 Sep 06, 2022	BUY	$1.76 - $3.33 $2,464 - $4,662	1,400 New	1,400 $13,000
Q2 2022 Aug 12, 2022	SELL	$1.76 - $3.33 $2,464 - $4,662	-1,400 Closed	0 $0
Q1 2022 Sep 06, 2022	SELL	$1.81 - $3.97 $181 - $397	-100 Reduced 6.67%	1,400 $4,000
Q4 2021 Jan 12, 2022	SELL	$3.66 - $8.22 $1,906 - $4,282	-521 Reduced 25.78%	1,500 $6,000
Q2 2021 Jul 13, 2021	BUY	$13.54 - $22.74 $27,364 - $45,957	2,021 New	2,021 $35,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.